CStone and LegoChem Biosciences enter into global licensing agreement


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ CStone and LegoChem Biosciences enter into global licensing agreement
This partnership puts LCB71 in a path to development and commercialization for patients around the world

CStone Pharmaceuticals announced a licensing agreement with LegoChem Biosciences, Inc., for the development and marketing of LCB71, a possible first-class / best-in-class antibody drug conjugate ("ADC").

Under the agreement, CStone obtains the exclusive worldwide right to lead the development and commercialization of LCB71 outside the Republic of Korea. LCB will receive an initial payment of US $ 10 million, and up to US $ 353.5 million in accumulated milestone payments, plus basic entitlements.

Frank Jiang , MD, Ph.D., President and CEO of CStone, said: "We are very pleased to form this partnership with LCB, a leading ADC platform company, to obtain global rights to an asset with highly differentiated attributes in an exciting new field of oncology. The agreement adds the first ADC to CStone's development process, and reinforces our precision medicine franchise with a new modality. We look forward to harnessing its full potential and bringing it to patients around the world. "

LCB71 is a preclinical ADC entering New Drug Investigation (IND) allowing studies. It targets ROR1 (Receptor Tyrosine Kinase as Orphan Receptor 1), a high potential ADC target for multiple solid and hematologic malignancies. ROR1 protein expression is prevalent in a variety of cancers, including various forms of leukemia, non-Hodgkin lymphoma, and breast, lung, and ovarian cancers.

LCB71 has a proprietary tumour-activated pyrrolobenzodiazepine ("PBD") prodrug toxin that addresses the typical toxicity problem associated with traditional PBD payloads. It has demonstrated complete tumour inhibition in several preclinical cancer models, which can translate into a broad therapeutic index for a range of solid and hematologic malignancies. In addition, it uses site-specific conjugation for a precise ratio of drug antibodies. This supports the serum half-life and improves its pharmacokinetic profile, and also allows for homogeneous production and large-scale manufacturing.

Dr Yong-Zu Kim, CEO and President of LCB, said: "We are pleased to have reached this agreement with CStone, which has demonstrated extensive experience in oncology, especially in global clinical development. This partnership puts LCB71 in a path to development and commercialization for patients around the world. We are convinced that CStone is the right partner to secure the future of this important drug. "

Tags : #CStonePharmaceuticals #LatestNewsonCStonePharmaceuticals #LegoChemBiosciences #LatestNewsnLegoChemBiosciences29thOct #LatestPharmaCollaboration29thOct #LatestPharmaNews29thOct #Cancers #FrankJiang #RepulicofKorea #DrYong-ZuKim

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026